Rob Rutledge
Managing Director
Get their honest, personalized take on your startup.
Sign in to pitch Rob →At a glance
- Full Name
- Rob S. Rutledge
- Title
- Managing Partner (promoted to Managing Director in 2015)
- Firm
- Genstar Capital
- Firm Type
- Middle-market private equity / control buyouts (NOT an angel investor — see note below)
- Investment Stage
- Control / control-equity investments in established middle-market companies (not seed-stage angel investing)
- Check Size
- Not publicly disclosed; Genstar deploys out of its ~$12.6B Fund XI (2023) into middle-market control deals, typically equity checks in the hundreds of millions
- Target Company Profile
- Established, profitable middle-market companies headquartered primarily in North America, acquired via control/buyout
- Sector Focus
- Industrials (Rutledge heads Genstar's industrials/industrial technology practice); firm-wide focus on financial services, healthcare, industrials, and software
- Geographic Focus
- North America
- Location
- San Francisco, California
Background
Rob Rutledge is a Managing Partner at Genstar Capital, a San Francisco-based private equity firm that invests in the financial services, healthcare, industrials, and software sectors. He first joined Genstar as an Associate in 2003, working to identify, evaluate, and execute acquisition and investment opportunities. He left to earn his MBA at Stanford University's Graduate School of Business and rejoined the firm in 2007, rising through the ranks to Managing Director (a promotion announced in January 2015) and ultimately to Managing Partner.
Rutledge began his career in the investment banking division of Salomon Smith Barney, working in San Francisco and New York, where he advised on mergers, acquisitions, and capital-markets offerings. He holds a Bachelor of Commerce (Honors) from Queen's University in Canada in addition to his Stanford MBA.
Within Genstar, Rutledge heads the firm's industrials practice, building the vertical through platform investments, targeted add-on acquisitions, and a network of operating advisors. He led Genstar's investments in MW Industries and Tecomet and was central to the firm's successful exit of Woods Equipment Company. Genstar's portfolio pages have also listed him on deal teams for companies such as ACA Group and Signant Health.
As one of Genstar's five Managing Partners (alongside Ryan Clark, Jean-Pierre Conte, Tony Salewski, and Eli Weiss), Rutledge is part of the leadership group steering a firm whose most recent flagship vehicle, Genstar Capital Partners XI, closed in April 2023 with approximately $12.6 billion of committed capital plus co-investment "overage" capacity — up from $10.2 billion for Fund X in 2021.
Investment Thesis & Focus
- Invests via control/buyout private equity, not venture or angel/seed capital — Genstar takes control positions in established, cash-generative middle-market companies.
- Sector lead for industrials / industrial technology; the firm as a whole concentrates on four verticals: financial services, healthcare, industrials, and software.
- Builds verticals through a "platform + add-on" strategy — acquiring a platform company, then compounding value with targeted bolt-on acquisitions and operating advisors, as described by Chairman Jean-Pierre Conte: Rutledge "continues to build this vertical with platform investments, targeted add-on acquisitions and operating advisors."
- Focuses on North American-headquartered middle-market companies.
- Value creation is driven by operational improvement and M&A roll-up over a multi-year hold, culminating in a strategic or sponsor exit (e.g., the Woods Equipment exit).
Notable Investments
- MW Industries — Manufacturer of springs, fasteners, and specialty engineered components; a platform Rutledge led in Genstar's industrials practice.
- Tecomet — Contract manufacturer of precision components for the medical device and aerospace/defense markets; another Rutledge-led industrials platform.
- Woods Equipment Company — Manufacturer of attachments/equipment for tractors and construction machinery; Rutledge was key to Genstar's exit of this investment.
- ACA Group — Governance, risk, and compliance advisory/technology provider for financial services; Rutledge listed on the Genstar deal team.
- Signant Health — Clinical-trial technology and eCOA/patient-data company; Rutledge listed on the Genstar deal team.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.